OmniAb Inc. (OABI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $716.17M
Last updated: Nov 17, 2026 at 11:06 AM ET
OmniAb Inc. (OABI) Earnings: Report Dates and Results
OmniAb (OABI) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, OmniAb reported EPS of -$0.12, in line with the -$0.12 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OABI has an expected report date of Mar 2, 2027.
OABI Earnings Call
The latest OABI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 16 quarters below that had an estimate, OABI beat 6, missed 6 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $3.99M, up 78.1% from $2.24M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.12 | -$0.12 | -$0.14 - -$0.12 | 0.00% | In line | N/A | 4 | 1 up, 3 down | Oct 30, 2026 | $3.99M |
| Jun 30, 2026 | -$0.05 | -$0.11 | N/A | +54.55% | Beat | N/A | 4 | 0 up, 3 down | Aug 6, 2026 | $13.41M |
| Mar 31, 2026 | -$0.06 | -$0.10 | -$0.11 - -$0.09 | +40.00% | Beat | N/A | 3 | 1 up, 0 down | May 7, 2026 | $14.43M |
| Dec 31, 2025 | -$0.11 | -$0.09 | -$0.11 - -$0.07 | -25.71% | Miss | N/A | 4 | 1 up, 0 down | Mar 4, 2026 | $8.38M |
| Sep 30, 2025 | -$0.14 | -$0.14 | -$0.15 - -$0.12 | 0.00% | In line | N/A | 5 | 1 up, 1 down | Nov 4, 2025 | $2.24M |
| Jun 30, 2025 | -$0.15 | -$0.15 | -$0.19 - -$0.14 | 0.00% | In line | N/A | 6 | 2 up, 0 down | Aug 6, 2025 | $3.90M |
| Mar 31, 2025 | -$0.17 | -$0.17 | -$0.19 - -$0.15 | 0.00% | In line | N/A | 6 | 0 up, 1 down | May 8, 2025 | $4.15M |
| Dec 31, 2024 | -$0.12 | -$0.10 | -$0.11 - -$0.08 | -24.10% | Miss | N/A | 6 | 2 up, 1 down | Mar 18, 2025 | $10.80M |
| Sep 30, 2024 | -$0.16 | -$0.14 | -$0.16 - -$0.12 | -14.29% | Miss | N/A | 8 | 0 up, 0 down | Nov 12, 2024 | $4.17M |
| Jun 30, 2024 | -$0.13 | -$0.17 | -$0.20 - -$0.13 | +23.53% | Beat | N/A | 7 | 0 up, 0 down | Aug 8, 2024 | $7.61M |
| Mar 31, 2024 | -$0.19 | -$0.16 | -$0.20 - -$0.12 | -18.75% | Miss | N/A | 8 | 0 up, 0 down | May 9, 2024 | $3.80M |
| Dec 31, 2023 | -$0.14 | -$0.15 | -$0.20 - -$0.11 | +6.67% | Beat | -300.0% | 8 | 0 up, 0 down | Mar 20, 2024 | $4.82M |
| Sep 30, 2023 | -$0.16 | -$0.13 | -$0.16 - -$0.11 | -23.08% | Miss | N/A | 7 | 0 up, 1 down | Nov 9, 2023 | $5.48M |
| Jun 30, 2023 | -$0.15 | -$0.12 | -$0.15 - -$0.05 | -25.00% | Miss | N/A | 7 | 0 up, 0 down | Aug 10, 2023 | $6.95M |
| Mar 31, 2023 | -$0.06 | -$0.13 | -$0.15 - $0.20 | +53.85% | Beat | N/A | 7 | 0 up, 0 down | May 11, 2023 | $16.92M |
| Dec 31, 2022 | $0.07 | $0.02 | -$0.16 - $0.09 | +250.00% | Beat | N/A | 5 | 0 up, 2 down | Mar 30, 2023 | $35.34M |
| Sep 30, 2022 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2022 | $6.91M |
| Jun 30, 2022 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 12, 2022 | $7.20M |
| Mar 31, 2022 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 20, 2022 | $9.62M |
| Dec 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 25, 2022 | $15.28M |
| Sep 30, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2021 | N/A |
| Jun 30, 2021 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Sep 23, 2021 | N/A |
| Mar 31, 2021 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Jun 29, 2021 | $6.60M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.57, after -$0.60 the year before. It was -$0.02 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.57 | N/A |
| Dec 31, 2024 | -$0.60 | N/A |
| Dec 31, 2023 | -$0.51 | N/A |
| Dec 31, 2022 | -$0.24 | N/A |
| Dec 31, 2021 | -$0.02 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,500 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,485 | 11 | |
| 2026Q2 | Jun 30, 2026 | 5,874 | 9 | |
| 2026Q1 | Mar 31, 2026 | 6,417 | 9 | |
| 2025Q4 | Dec 31, 2025 | 5,998 | 10 | |
| 2025Q3 | Sep 30, 2025 | 5,671 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,993 | 7 | |
| 2025Q1 | Mar 31, 2025 | 4,715 | 8 | |
| 2024Q4 | Dec 31, 2024 | 6,546 | 6 |
2026Q3 Earnings Call
Opening remarks
Kurt Gustafson Chief Financial Officer Thank you, operator, and good morning, everyone. This is Kurt Gustafson, OmniAb's Chief Financial Officer, and thank you all for joining our third quarter 2026 financial results conference call. There are slides to accompany today's prepared remarks, and they're available in the Investors section of our website at omniab.com. Before we begin, I'd like to remind listeners that comments made during this call by OmniAb's management will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from any of the anticipated results. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast today, October 30, 2026. Except as required by law, OmniAb undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Joining me this morning is Matt Foehr, OmniAb's President and CEO, and Amechi Nwachuku, our Chief Operating Officer. During today's call, Matt is going to cover some highlights. Amechi will provide an update on our xPloration program, and I'll go through our financial results and guidance, and then we'll open up the call to questions. And with that, let me turn the call over to Matt.
Matthew Foehr President and CEO Thanks, Kurt. Good morning, everyone, and thanks for joining our third quarter call. I'll start now on Slide number 4, which includes some highlights from the third quarter. Our business here at OmniAb has been designed to benefit from diversified, long-term, and durable revenue streams. We continued to drive strong performance in the third quarter as our highly differentiated technology platforms are facilitating growth in partnerships and progression of programs. We have been and continue to be very active from a licensing perspective and announced a major new deal in the quarter with Eli Lilly for a novel ion channel program. We were really pleased to enter into this important new relationship with Lilly, as they're obviously focused on delivering medicines to address major unmet medical needs, and our differentiated expertise and established technologies that specifically relate to ion channels are well positioned to help facilitate that and drive this new discovery program forward. Under the terms of that license deal, we received an upfront payment and are eligible to receive up to $370 million in research, development, and commercial milestone payments, as well as potential tiered royalties on global net sales. In Q3, we saw increased utilization of our differentiated technologies within our growing ecosystem of partners.
Frequently Asked Questions About OABI
When is OmniAb's next earnings date?
OmniAb's next earnings report is expected for Mar 2, 2027.
Did OABI beat earnings estimates last quarter?
OmniAb reported EPS of -$0.12 for the quarter ended Sep 30, 2026, in line with the -$0.12 estimate.
What EPS do analysts expect from OABI next quarter?
The consensus EPS estimate for OmniAb for the quarter ending Dec 31, 2026 is -$0.12 from 9 analysts, with estimates from -$0.13 to -$0.12.
How often does OABI beat earnings estimates?
OmniAb beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of +5.59%.
OABI pages: Overview, Earnings, Forecast, Financials, Competitors